Procyrion is dedicated to improving the quality of life of millions of heart failure patients through the development of safe and innovative circulatory assist devices. Procyrion is currently engaged in the development of the Aortix heart pump, designed to be the first non-surgical, minimally invasive, catheter deployed heart pump for long-term use. Aortix may improve the quality of life of millions of NYHA Stage III and early Stage IV heart failure patients.
To deliver on our commitments to patients and healthcare providers, Sorin Group teams continue to research, develop, and deliver reliable and state-of-the-art therapeutic solutions that address unmet cardiovascular needs and improve patient outcomes.
BioStable Science and Engineering is a cardiovascular device company focused on developing and commercializing proprietary valve repair technologies that provide an alternative to valve replacement for patients with aortic valve disease.